Prana Biotech +15% on favorable PBT434 pre-clinical results

Prana Biotech +15% on favorable PBT434 pre-clinical results


Prana Biotechnology jumps as much as 25% after disclosing that the article "The novel compound PBT434 prevents iron-mediated neurodegeneration and alpha-synuclein toxicity in multiple models of Parkinson's disease" was accepted for publication in the peer reviewed journal Acta Neuropathologica Communications . Prana says the article includes pre-clinical data that shows its PBT434 drug candidate lowers levels of alpha-synuclein, a brain protein widely believed to be involved in the pathogenesis of Parkinson's disease and related disorders.



from Biotech News